Supernus Pharmaceuticals, Inc. (SUPN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.52B
Last updated: Nov 17, 2026 at 11:06 AM ET
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecast
Analysts expect Supernus Pharmaceuticals (SUPN) to earn $4.42 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.33B. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 25.0% |
| Buy | 3 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 2.0% and revenue estimates rise 5.3%.
- Fiscal year ending Dec 31, 2026
- $4.42
- EPS consensus, revenue $1.33B
- Fiscal year ending Dec 31, 2027
- $4.51
- EPS consensus, revenue $1.40B
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $4.42 | $4.36 to $4.47 | 2 | $1.33B | $1.32B to $1.34B | 3 |
| Dec 31, 2027 | $4.51 | $3.89 to $4.89 | 3 | $1.40B | $1.37B to $1.41B | 3 |
Quarterly Estimates
The EPS consensus falls from $1.20 for the quarter ending Dec 31, 2026 to $0.94 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.20 | $1.07 to $1.28 | 6 | $342.31M | $324.38M to $361.52M | 5 |
| Mar 31, 2027 | $0.94 | $0.86 to $1.02 | 2 | $328.00M | $328.00M to $328.00M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 8 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Fiscal year ending Dec 31, 2027 | 3 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 14.8% from $3.85.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $4.42 | $4.41 | $4.41 | $4.41 | $3.85 | +14.5% |
| Fiscal year ending Dec 31, 2027 | $4.51 | $4.88 | $4.88 | $4.88 | $4.17 | +8.1% |
| Quarter ending Mar 31, 2027 | $0.94 | $1.08 | $1.08 | $1.08 | $0.98 | -3.7% |
Frequently Asked Questions About SUPN
What is the SUPN stock forecast?
Consensus analyst estimates put Supernus Pharmaceuticals's EPS at $4.42 for the fiscal year ending Dec 31, 2026, on revenue of $1.33B. The consensus rating from 4 analysts is Buy.
How do analysts rate SUPN stock?
Of 4 analysts covering Supernus Pharmaceuticals, 1 rates it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SUPN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $4.42, with estimates from $4.36 to $4.47 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $4.51, with estimates from $3.89 to $4.89 from 3 analysts.
What revenue do analysts expect from Supernus Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.33B, with estimates from $1.32B to $1.34B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.40B, with estimates from $1.37B to $1.41B.
How many analysts cover SUPN?
4 analysts rate Supernus Pharmaceuticals stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SUPN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors